NIH RFA · NCI · R33
RFA-CA-27-002: Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites grant applications proposing exploratory research projects focused on further development and technical validation of emerging technologies offering novel capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens used for basic, clinical, or epidemiological cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous technical validation to encourage…
- NOFO number
- RFA-CA-27-002
- Type
- RFA
- Activity code
- R33
- Primary institute
- NCI · National Cancer Institute
- Clinical trials
- Not Allowed
- Posted
- Jun 3, 2026
- Opens
- Jun 10, 2026
- Expires
- Nov 11, 2026
RFA-CA-27-002 due dates
1 application due date remains before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| July 10, 2026 | July 10, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| November 10, 2026 | November 10, 2026 | Not Applicable | February 2027 | May 2027 | July 2027 |
What its predecessor RFA-CA-25-002 funded
RFA-CA-27-002 reissues RFA-CA-25-002. Until awards appear under the new number, its funding history is the best guide to who wins under this program: 10 projects and $4.1M in FY2022–FY2026.
Projects funded
10
Distinct projects, FY2022–FY2026
New awards
10
Type 1 (new project) award records
NIH funding
$4.1M
Award dollars under RFA-CA-25-002, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 10 | 10 | $4.1M |
Institutions with the most funding
- Yale University$837K · 2 projects
- Jackson Laboratory$452K · 1 project
- Dana-Farber Cancer Inst$432K · 1 project
- Beth Israel Deaconess Medical Center$431K · 1 project
- University of Connecticut Sch of Med/Dnt$415K · 1 project
- University of Washington$405K · 1 project
- Duke University$402K · 1 project
- University of Chicago$388K · 1 project
Funding institutes
- NCI$4.1M · 10
Activity codes funded
- R3310 records
Most recent new awards
- Advanced development and validation of Cas12a family based multiplexed genetic perturbation tools for cancer and immunology (opens NIH RePORTER)
Yale University · 1R33CA302629-01A1 · NCI · Notice Sep 17, 2026
$418KR33
- Developing whole-genome spatial transcriptomic imaging and advanced in vivo screening platforms in cancer (opens NIH RePORTER)
Yale University · 1R33CA315126-01 · NCI · Notice Sep 14, 2026
$418KR33
- Gene delivery to antigen-specific T cells via targeted retroviral vectors to treat cancer (opens NIH RePORTER)
Dana-Farber Cancer Inst · 1R33CA302616-01A1 · NCI · Notice Aug 17, 2026
$432KR33
- Cost-Effective, Submicron-Resolution Spatial Immunosequencing and Transcriptomics for Precision Immuno-Oncology (opens NIH RePORTER)
University of Washington · 1R33CA309730-01A1 · NCI · Notice Aug 13, 2026
$405KR33
- Biosensor Selection of Tumor-Reactive Tumor Infiltrating Lymphocytes (opens NIH RePORTER)
Pennsylvania State University, the · 1R33CA302535-01A1 · NCI · Notice Jul 28, 2026
$382KR33
- SnoRNA targetome and application to cancer (opens NIH RePORTER)
University of Chicago · 1R33CA309701-01 · NCI · Notice Jul 17, 2026
$388KR33
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under RFA-CA-27-002. Contact the program officer at the institute that fits your research before applying.
- NCI · National Cancer Institute
- none
Related notices
NIH lists no related notices for RFA-CA-27-002 yet.
Award terms
- Application types allowed
- New Resubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are limited to 300,000 per year in direct costs).
- Project period
- The total project period request may not exceed 3 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- NCI intends to fund an estimate of 13 awards, corresponding to a total of 5,900,000, for the fiscal year 2027. Future year amounts will depend on annual appropriations.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of RFA-CA-25-002.
- Companion NOFOs: RFA-CA-27-001.
Other open NOFOs for R33
- RFA-AI-27-018Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)NIAID · next due Nov 10, 2026
- RFA-NS-25-023HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)NINDS · next due Jan 15, 2027
- PAR-25-210Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)NCCIH · next due Jun 2, 2027
- PAR-25-211Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)NCCIH · next due Jun 2, 2027
- RFA-OD-27-005INCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)OD · next due Jun 15, 2027
- PAR-25-158Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)NIAAA · next due Oct 19, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.